Results 141 to 150 of about 4,153 (212)

Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease. [PDF]

Medicine (Baltimore)
Chen K, Shao W, Zhang H.
europepmc   +1 more source

Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis. [PDF]

Kidney Dis (Basel)
Li P, An Y, Zheng H, Lu W, Mo Z, Xu X, Lu Y, Wu C, Xie J, Tong N, Liu F, Chen Q, Tang J, Brinker M, Roberts L, Zhu D, Liu Z.   +16 more
europepmc   +1 more source

Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration. [PDF]

Eur Heart J Cardiovasc Pharmacother
Chen YH, Fang YW, Tsai MH.
europepmc   +1 more source

External Control Augmentation Increases Estimates Precision for Finerenone plus Sodium-Glucose Cotransporter-2 Inhibitors. [PDF]

Kidney Int Rep
Boemmel-Wegmann SV, Bauer C, Zerck A, Hartenstein A, Schuchhardt J, Knapp R, Edfors R, Farjat AE, Walsh M.   +8 more
europepmc   +1 more source

Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. [PDF]

Front Pharmacol
Wang TY, Zhang L, Wang HY, Jiang FF.
europepmc   +1 more source

The Case for Combination Treatment of CKD in Type 2 Diabetes Mellitus. [PDF]

Kidney Int Rep
Curovic VR.
europepmc   +1 more source

Real-World Impact of Finerenone on Albuminuria in Patients with Diabetes and CKD. [PDF]

Int J Mol Sci
López-Martínez M, León-Román J, Suárez E, Nuñez-Delgado S, Antonieta Azancot M, Zamora-Carrillo JI, Patricio-Liébana M, Sánchez Olaya A, Agraz I, Bermejo S, Sans L, Toapanta N, Ramos N, Soler MJ.   +13 more
europepmc   +1 more source

Effect of finerenone on proteinuria reduction in IgA nephropathy. [PDF]

Ren Fail
Yu G, Wang M, Zhang X, Tao J, Zhao J, Liu S, Zhou S, Zhou J, Ren P, Cheng J, Chen J.   +10 more
europepmc   +1 more source

Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024. [PDF]

Front Pharmacol
Ji K, Huang X, Wang F, Zhang L, Zheng Y, Ji L, Ju Y, Zhuang X, Li J.   +8 more
europepmc   +1 more source

Impact of Finerenone in Patients with Heart Failure and Reduced/Mildly Reduced Ejection Fraction, Diabetes Mellitus, and Chronic Kidney Disease. [PDF]

J Clin Med
Hida Y, Imamura T, Kinugawa K.
europepmc   +1 more source